We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
Subclinical CVdisease was associated with age and dyslipidemia but not with other risk factors.
2
These effects seem particularly important for reducing risk of CVdisease in patients with the metabolic syndrome.
3
This study provides preliminary data for developing an integrated model of multidisciplinary care for the management of CVdisease.
4
Increasing the understanding of the pathogenesis of various CVdiseases may provide novel therapeutic targets to improve their prevention and treatment.
5
The metabolic syndrome (MS) represents a cluster of cardiovascular (CV ) risk factors associated to CVdisease and type 2 diabetes.
6
Additionally, recent studies suggest that GnRH antagonists may significantly reduce CV risk compared to GnRH agonists, particularly in men with pre-existing CVdisease.
7
Because AstraZeneca's study also looked at patients without established CVdisease, it potentially opens up a larger market that also covers so-called primary prevention.
8
Coronary and CVdisease biomarkers in UWS correlated better with serum than with LS and GS based on group status and measures of time effect.